Discover
TSHA
Taysha Gene Therapies, Inc.
5.67
1 x 5.13
1 x 5.91
bid
ask
+
0.09
1.61%
166 @ 04:00 PM
5.91 +0.24 (4.29%)
| Ytd | 3.09% | |
| 1y | 115.59% |
5.59
day range
5.78
2.34
52 week range
7.30
| Open | 5.62 | Prev Close | 5.58 | Low | 5.59 | High | 5.78 | Mkt Cap | 1.42B |
| Vol | 1.85M | Avg Vol | 3.04M | EPS | -0.38 | P/E | -14.92 | Forward P/E | -14.57 |
| Beta | 1.17 | Short Ratio | 10.84 | Inst. Own | 86.20% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 6.05 | 200-d Avg | 5.22 | 1yr Est | 13.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -0.11 | N/A | N/A | N/A |
| 2026-05-06 | 2026-03 | -0.1 | -0.12 | -0.02 | -20.00% |
| 2026-03-19 | 2025-12 | -0.11 | -0.08 | 0.03 | 27.27% |
| 2025-11-04 | 2025-09 | -0.09 | -0.09 | N/A | N/A |
| 2025-08-12 | 2025-06 | -0.07 | -0.09 | -0.02 | -28.57% |
| 2025-05-15 | 2025-03 | -0.08 | -0.08 | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-07-02 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2026-06-30 | Needham | Upgrade | Buy | Buy |
| 2026-06-30 | Baird | Upgrade | Outperform | Outperform |
| 2026-06-23 | BMO Capital | Upgrade | Outperform | Outperform |
| 2026-06-23 | B of A Securities | Upgrade | Buy | Buy |
| 2026-06-23 | Citizens | Upgrade | Market Outperform | Market Outperform |
Profile
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-03 | ALAM KAMRAN | Chief Financial Officer | 1.44M | Sale |
| 2026-05-31 | DONENBERG PHILLIP BRIAN | Director | 241.29K | Stock Award(Grant) |
| 2026-05-31 | LONG ALISON S | Director | 127.18K | Stock Award(Grant) |
| 2025-05-29 | MANNING PAUL B. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-07-09 | NAGENDRAN SUKUMAR | Officer and Director | 936.41K | Sale |
| 2026-01-25 | NOLAN SEAN PATRICK | Chief Executive Officer | 4.44M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | RA Capital Management, LLC | 23.56M | 0.00 | 7.36% |
| 2026-03-30 | The Goldman Sachs Group Inc | 22.37M | 0.00 | 6.99% |
| 2026-03-30 | venBio Select Advisor LLC | 21.70M | 0.00 | 6.78% |
| 2026-03-30 | BlackRock Inc | 18.37M | 0.00 | 5.74% |
| 2026-03-30 | Vestal Point Capital LP | 18.00M | 0.00 | 5.63% |
| 2026-03-30 | Morgan Stanley - Brokerage Accounts | 17.97M | 0.00 | 5.62% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Vanguard Total Stock Mkt Idx Inv | 9.14M | 0.00 | 2.86% |
| 2026-06-29 | iShares Russell 2000 ETF | 6.28M | 0.00 | 1.96% |
| 2026-06-29 | State Street® SPDR® S&P® Biotech ETF | 5.55M | 0.00 | 1.73% |
| 2026-05-30 | Fidelity Growth Compy Commingled Pl S | 5.46M | 0.00 | 1.71% |
| 2026-05-30 | Fidelity Growth Company Fund | 4.18M | 0.00 | 1.31% |
| 2026-05-30 | Polar Capital Biotech S Inc | 3.66M | 0.00 | 1.15% |